FLUXOETINE VS PLACEBO IN ADULT AUTISTIC DISORDER

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Autism, originally described by Kanner in 1943, is among the most severe of all neuropsychiatric disorders. It is a pervasive developmental disorder affecting social, communicative, and compulsive/repetitive behaviors characterized by stereotypic complex hand and body movements, craving for sameness, and narrow repetitive interests (American Psychiatric Press, 1994). Autism severely impacts both the affected individual and family members and causes life-long functional impairment. This study will assess the efficacy and safety of fluoxetine, a selective serotonin reuptake inhibitor (SSR) vs. placebo in treatment of adult autistic disorder (AD) global severity, via a 12 week double-blind, placebo-controlled parallel study.